Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review

Pujade-Lauraine, Éric; Tan, David Sp; Leary, Alexandra; Mirza, Mansoor Raza; Enomoto, Takayuki; Takyar, Jitender; Nunes, Ana T.; Chagüi, José David Hernández; Paskow, Michael; Monk, Bradley J.

doi:10.1016/j.ygyno.2022.08.013

Cited by 14 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As tumors progress to regional or distant disease, surgery becomes less likely to be curative. At this point, radiotherapy and/or chemotherapy (most often a platinum‐based drug) becomes the standard approach 7 . Both approaches work by causing largely indiscriminate DNA damage, achieving some degree of specificity since DNA damage is more lethal in replicating cells and tumor cells are more likely to be replicating than other cells.…”

Section: Overview Of Current Chemotherapy and Radiotherapy Interventi...mentioning

confidence: 99%

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

Wendel,

Snow,

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Cervical cancers are the fourth most common and most deadly cancer in women worldwide. Despite being a tremendous public health burden, few novel approaches to improve care for these malignancies have been introduced. We discuss the potential for proliferating cell nuclear antigen (PCNA) inhibition to address this need as well as the advantages and disadvantages for compounds that can therapeutically inhibit PCNA with a specific focus on cervical cancer.

show abstract

Section: Overview Of Current Chemotherapy and Radiotherapy Interventi...mentioning

confidence: 99%

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

Wendel,

Snow,

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Concurrent radiotherapy is the standard treatment modality for LACC patients, however, the efficacy is limited, especially for those with stage III/IV disease ( 6 ). Thus, the addition of immunotherapy may be of particular benefit to late-stage patients.…”

Section: Summary and Prospectsmentioning

confidence: 99%

“…Concurrent chemoradiotherapy (CCRT) is the standard of care for patients with locally advanced cervical cancer (LACC), also known as International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IB3, IIA2-IVA ( 6 ). There are no significant differences in the prognosis of squamous and adenocarcinoma patients who are receiving CCRT, and the overall survival (OS) rate is longer than it is for patients receiving radiotherapy alone ( 7 , 8 ).…”

Section: Introductionmentioning

confidence: 99%

Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data

Song

Zou

2022

Front. Oncol.

View full text Add to dashboard Cite

Immunotherapy has shown great promise in the field of oncology, and recent clinical trials have illustrated that immune checkpoint blockade (ICB) is safe and effective at treating a range of tumor types. Cervical cancer (CC) is the fourth most common malignancy in women. However, first-line treatments for locally advanced cervical cancer (LACC) and recurrent/metastatic (R/M) CC have limited efficacy. Thus, it is necessary to explore new treatment approaches. The National Comprehensive Cancer Network (NCCN) currently recommends pembrolizumab, a programmed cell death protein 1 (PD-1) monoclonal antibody, as a first line therapy for individuals with R/M CC. This study reviews the progress of ICB therapy for LACC and R/M CC and describes the current status of the combination of ICB therapy and other therapeutic modalities, including radiotherapy, chemotherapy, targeted therapy, and other immunotherapies. The focus is placed on studies published since 2018 with the aim of highlighting novel CC-specific immunotherapeutic approaches and treatment targets.

show abstract

“…In this context, the International Federation of Obstetrics and Gynecology (FIGO) system has included lymph node status in the staging classification in 2018; LACC includes stages IB to IVA tumors [ 4 ]. International treatment guidelines recommend platinum-based concurrent chemoradiotherapy (CCRT) as the standard treatment for LACC [ 5 , 6 ]. Notably, the 5-year overall survival (OS) for locally advanced and metastatic cervical cancer is estimated to be approximately 65% and 17%, respectively [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a 18F-FDG PET/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study

Liu,

Cui,

Chang

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background The existing staging system cannot meet the needs of accurate survival prediction. Accurate survival prediction for locally advanced cervical cancer (LACC) patients who have undergone concurrent radiochemotherapy (CCRT) can improve their treatment management. Thus, this present study aimed to develop and validate radiomics models based on pretreatment 18Fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)-computed tomography (CT) images to accurately predict the prognosis in patients. Methods The data from 190 consecutive patients with LACC who underwent pretreatment 18F-FDG PET-CT and CCRT at two cancer hospitals were retrospectively analyzed; 176 patients from the same hospital were randomly divided into training (n = 117) and internal validation (n = 50) cohorts. Clinical features were selected from the training cohort using univariate and multivariate Cox proportional hazards models; radiomic features were extracted from PET and CT images and filtered using least absolute shrinkage and selection operator and Cox proportional hazard regression. Three prediction models and a nomogram were then constructed using the previously selected clinical, CT and PET radiomics features. The external validation cohort that was used to validate the models included 23 patients with LACC from another cancer hospital. The predictive performance of the constructed models was evaluated using receiver operator characteristic curves, Kaplan Meier curves, and a nomogram. Results In total, one clinical, one PET radiomics, and three CT radiomics features were significantly associated with progression-free survival in the training cohort. Across all three cohorts, the combined model displayed better efficacy and clinical utility than any of these parameters alone in predicting 3-year progression-free survival (area under curve: 0.661, 0.718, and 0.775; C-index: 0.698, 0.724, and 0.705, respectively) and 5-year progression-free survival (area under curve: 0.661, 0.711, and 0.767; C-index, 0.698, 0.722, and 0.676, respectively). On subsequent construction of a nomogram, the calibration curve demonstrated good agreement between actually observed and nomogram-predicted values. Conclusions In this study, a clinico-radiomics prediction model was developed and successfully validated using an independent external validation cohort. The nomogram incorporating radiomics and clinical features could be a useful clinical tool for the early and accurate assessment of long-term prognosis in patients with LACC patients who undergo concurrent chemoradiotherapy.

show abstract

Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review

Cited by 14 publications

References 42 publications

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data

Development and validation of a 18F-FDG PET/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study

Contact Info

Product

Resources

About